Statin use linked to lower prostate cancer death risk

by Alan Mozes, Healthday Reporter
Statin use linked to lower prostate cancer death risk
Canadian researchers say findings aren't proof, call for more studies.

(HealthDay)—Prostate cancer patients who take the cholesterol-lowering drugs known as statins appear to face a lower risk of death from their disease, new Canadian research suggests.

The decreased risk was strongest for those who were taking the statins before their cancer diagnosis, investigators found. In addition, the study also showed, statin use was associated with a lower risk for any cause of death.

Despite the evidence, however, the study team called for more research to confirm the findings.

"The results of our study suggest that the use of statins is associated with a decreased risk of prostate cancer mortality," said study co-author Laurent Azoulay, from Jewish General Hospital and McGill University in Montreal. "(But) overall, while our results are very promising, we believe that additional rigorous studies are needed before prescribing these agents to men with prostate cancer."

Azoulay and his colleagues, whose study is published online ahead of print in the Journal of Clinical Oncology, noted that they did not show a direct cause-and-effect relationship between the popular drugs taken by millions to prevent heart disease and a lower death risk from prostate cancer.

To explore the protective potential of statins, which are sold under such brand names as Zocor, Crestor and Lipitor, the authors analyzed data on almost 12,000 men from the United Kingdom who had been diagnosed with prostate cancer at some point between 1998 and 2009.

The men were tracked through 2012, for an average of more than four years after their diagnosis. During that time, nearly 3,500 died, and almost 1,800 of those deaths were attributed to prostate cancer.

Ultimately, Azoulay's team concluded that statin use was associated with both a lower risk of dying from prostate cancer as well as a lower risk of death from any cause. The protective effect attributed to statin use was strongest among those men who had begun using statins before they were diagnosed with prostate cancer.

At this point, the authors can only theorize on what the connection could be.

"In terms of their possible physiological effects, several experimental studies have shown that statins have anti-tumor properties on , such as on cell proliferation," Azoulay noted.

"The results of our study do corroborate these experimental studies," he added. "That being said, it is well-documented that long-term statin users are 'health-conscious' individuals. Thus, it is also possible that their healthy behavior may have contributed, at least in part, to the observed decreased risk with ."

But if further research upholds the current indications, would a statin regimen be advisable?

"Statins are generally safe drugs, though some rare adverse events can occur, such as muscle damage," Azoulay said. "This is especially relevant as certain prostate cancer treatments, such as androgen-deprivation therapy, may also affect muscle mass."

Future studies should assess whether statins can be used safely with other prostate cancer treatments, he added.

Dr. Anthony D'Amico, chief of radiation oncology at Brigham and Women's Hospital in Boston, suggested, however, the findings should be considered with caution.

"It is important to note that this is a study of association and not proof of cause and effect," he said, noting that only a large randomized trial can prove causation.

"Nevertheless, the study results are encouraging," he added, "and support a to validate their findings for use in the pre- and post-() diagnostic settings."

More information: For more on prostate cancer, visit the U.S. National Institutes of Health.

Related Stories

Cholesterol-lowering drugs may slow prostate growth

May 21, 2012

Statins drugs prescribed to treat high cholesterol may also work to slow prostate growth in men who have elevated PSA levels, according to an analysis led by researchers at Duke University Medical Center.

Implications of very low risk prostate cancer assessed

Sep 20, 2013

(HealthDay)—The risk of adverse findings at surgery for men with very low risk (VLR) prostate cancer is significantly lower than for those with low risk (LR), according to research published in the October ...

Recommended for you

Gene test aids cancer profile

14 hours ago

The first round of chemotherapy did little to suppress Ron Bose's leukemia. The second round, with 10 times the dose, knocked the proliferating blast cells down, but only by half.

User comments

Adjust slider to filter visible comments by rank

Display comments: newest first

marko
1 / 5 (2) Nov 05, 2013
The use of statins to lower cholesterol is one of the biggest scams in medicine.

Link to the documentary from ABC Catalyst Australia that discusses this topic.

Part 1 - Heart of the Matter Part 1 - Dietary Villains

http://www.abc.ne...6219.htm

Part 2 - Heart of the Matter Part 2 - Cholesterol Drug War

http://www.abc.ne...1441.htm
Mike_Massen
1.5 / 5 (2) Nov 06, 2013
The jury is still out on this, statins do have some anti-inflammatory properties and shouldn't necessarily be abandoned outright. It is unfortunate it appears the original research has flaws which can creep in (obviously) due to conflict of interest or outright manipulated prior selection criteria.

Rather than jump to a populist tv program marko, where are the best top 10 studies which have high level experimental evidence free from bias or funding from any group with a position on either side of the fence ?

This seems to be one those classic cases (to a degree) where there might be some influence but in a topic which has potentially wide areas of combinatorial complexity when most people love the naive notion of a yes/no ideal - which any mature researcher will quickly appreciate doesn't quite exist for the most part...

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.